<?xml version='1.0' encoding='utf-8'?>
<document id="32131538"><sentence text="Mertansine Inhibits mRNA Expression and Enzyme Activities of Cytochrome P450s and Uridine 5'-Diphospho-Glucuronosyltransferases in Human Hepatocytes and Liver Microsomes."><entity charOffset="0-10" id="DDI-PubMed.32131538.s1.e0" text="Mertansine" /></sentence><sentence text="Mertansine, a tubulin inhibitor, is used as the cytotoxic component of antibody-drug conjugates (ADCs) for cancer therapy"><entity charOffset="0-10" id="DDI-PubMed.32131538.s2.e0" text="Mertansine" /></sentence><sentence text=" The effects of mertansine on uridine 5'-diphospho-glucuronosyltransferase (UGT) activities in human liver microsomes and its effects on the mRNA expression of cytochrome P450s (CYPs) and UGTs in human hepatocytes were evaluated to assess the potential for drug-drug interactions (DDIs)"><entity charOffset="16-26" id="DDI-PubMed.32131538.s3.e0" text="mertansine" /></sentence><sentence text=" Mertansine potently inhibited UGT1A1-catalyzed SN-38 glucuronidation, UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-β-glucuronidation, and UGT1A4-catalyzed trifluoperazine N-β-d-glucuronidation, with Ki values of 13"><entity charOffset="1-11" id="DDI-PubMed.32131538.s4.e0" text="Mertansine" /></sentence><sentence text="5 µM, 4" /><sentence text="3 µM, and 21" /><sentence text="2 µM, respectively, but no inhibition of UGT1A6, UGT1A9, and UGT2B7 enzyme activities was observed in human liver microsomes" /><sentence text=" A 48 h treatment of mertansine (1"><entity charOffset="21-31" id="DDI-PubMed.32131538.s8.e0" text="mertansine" /></sentence><sentence text="25-2500 nM) in human hepatocytes resulted in the dose-dependent suppression of mRNA levels of CYP1A2, CYP2B6, CYP3A4, CYP2C8, CYP2C9, CYP2C19, UGT1A1, and UGT1A9, with IC50 values of 93" /><sentence text="7 109" /><sentence text="1, 36" /><sentence text="8 18" /><sentence text="3, 160" /><sentence text="6 167" /><sentence text="4, 32" /><sentence text="1 14" /><sentence text="9, 578" /><sentence text="4 452" /><sentence text="0, 539" /><sentence text="5 233" /><sentence text="4, 856" /><sentence text="7 781" /><sentence text="9, and 54" /><sentence text="1 29" /><sentence text="1 nM, respectively, and decreased the activities of CYP1A2-mediated phenacetin O-deethylase, CYP2B6-mediated bupropion hydroxylase, and CYP3A4-mediated midazolam 1-hydroxylase"><entity charOffset="68-78" id="DDI-PubMed.32131538.s25.e0" text="phenacetin" /><entity charOffset="109-118" id="DDI-PubMed.32131538.s25.e1" text="bupropion" /><pair ddi="false" e1="DDI-PubMed.32131538.s25.e0" e2="DDI-PubMed.32131538.s25.e0" /><pair ddi="false" e1="DDI-PubMed.32131538.s25.e0" e2="DDI-PubMed.32131538.s25.e1" /></sentence><sentence text=" These in vitro DDI potentials of mertansine with CYP1A2, CYP2B6, CYP2C8/9/19, CYP3A4, UGT1A1, and UGT1A9 substrates suggest that it is necessary to carefully characterize the DDI potentials of ADC candidates with mertansine as a payload in the clinic"><entity charOffset="34-44" id="DDI-PubMed.32131538.s26.e0" text="mertansine" /><entity charOffset="214-224" id="DDI-PubMed.32131538.s26.e1" text="mertansine" /><pair ddi="false" e1="DDI-PubMed.32131538.s26.e0" e2="DDI-PubMed.32131538.s26.e0" /><pair ddi="false" e1="DDI-PubMed.32131538.s26.e0" e2="DDI-PubMed.32131538.s26.e1" /></sentence><sentence text="" /></document>